Search

Sepiapterin

[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.

Propiomazine

Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. … Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism.

N-(2-Aminoethyl)-1-aziridineethanamine

First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

Insulin beef

Insulin beef has been discontinued in the US and Canada since 2017.[L10827]

Fostemsavir

prevents the first step in the HIV-1 viral lifecycle. … [A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant

Omaveloxolone

[L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

Iodamide

Iodamide is a contrast medium molecule that is no longer marketed in the United States.

Fluocortolone caproate

Sodium cellulose phosphate

[A31694] This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption.